CBD2: A functional biomarker database for colorectal cancer
Medical Research Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China
Department of Oncology and Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden
Department of Ophthalmology, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Guangdong Eye Institute, Southern Medical University, Guangzhou, China
Guangdong Provincial Key Laboratory of Artificial Intelligence in Medical Image Analysis and Application, Guangzhou, China
MOE Key Laboratory of Geriatric Diseases and Immunology, Suzhou Key Laboratory of Pathogen Bioscience and Anti‐infective Medicine, Department of Bioinformatics, Center for Systems Biology, School of Biology and Basic Medical Sciences, Suzhou Medical College of Soochow University, Suzhou, China
Department of Ultrasound, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China
Department of Orthopaedics, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China
Department of Critical Care Medicine and Institutes for Systems Genetics, Frontiers Science Center for Disease‐related Molecular Network, West China Hospital, Sichuan University, Chengdu, China
School of Laboratory Medicine and Bioengineering, Hangzhou Medical College, Hangzhou, China
School of Medicine, Institute of Medical Sciences, Örebro University, Örebro, Sweden
Department of Radiotherapy and Oncology, The Second Affiliated Hospital of Soochow University, Suzhou, China
Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden
Key Laboratory of Public Health Safety, School of Public Health, Fudan University, Shanghai, China
Department of Otolaryngology, Guangzhou Women and Children's Medical Centre, Guangzhou, China
School of Medicine, The Chinese University of Hong Kong, Shenzhen, Shenzhen, China
Department of Mathematics, University of California, San Diego, California, USA
Department of Radiology, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China
Institutes for Systems Genetics, Frontiers Science Center for Disease‐Related Molecular Network, West China Hospital, Sichuan University, Chengdu, China
Abstract
The rapidly evolving landscape of biomarkers for colorectal cancer (CRC) necessitates an integrative, updated repository. In response, we constructed the Colorectal Cancer Biomarker Database (CBD), which collected and displayed the curated biomedicine information for 870 CRC biomarkers in the previous study. Building on CBD, we have now developed CBD2, which includes information on 1569 newly reported biomarkers derived from different biological sources (DNA, RNA, protein, and others) and clinical applications (diagnosis, treatment, and prognosis). CBD2 also incorporates information on nonbiomarkers that have been identified as unsuitable for use as biomarkers in CRC. A key new feature of CBD2 is its network analysis function, by which users can investigate the visible and topological network between biomarkers and identify their relevant pathways. CBD2 also allows users to query a series of chemicals, drug combinations, or multiple targets, to enable multidrug, multitarget, multipathway analyses, toward facilitating the design of polypharmacological treatments for CRC. CBD2 is freely available at http://www.eyeseeworld.com/cbd.
Untitled section
Keywords: biomarker, colorectal cancer, database, network analysis
Graphical
CBD2 integrates biomarkers derived from diverse biological sources and clinical applications, employing a standardized approach for annotation and classification. CBD2 facilitates precision medicine in colorectal cancer by providing abundant data, including drug–target information and visualized network analysis functions. With its user‐friendly interface, CBD2 aids in the identification and development of biomarkers for colorectal cancer.
Boxed Text
Highlights
- CBD2 integrates biomarkers derived from diverse biological sources and clinical applications, employing a standardized approach for annotation and classification.
- CBD2 facilitates precision medicine in colorectal cancer by providing abundant data, including drug–target information and visualized network analysis functions.
- With its user‐friendly interface, CBD2 aids in the identification and development of biomarkers for colorectal cancer.
Article notes
Untitled section
Received 2023 Oct 10; Accepted 2023 Nov 7; Collection date 2024 Feb.
INTRODUCTION
Colorectal cancer (CRC) remains a major global challenge in terms of its diagnosis, treatment, and prognosis, despite being the third most prevalent cancer worldwide [1]. Biomarkers have been demonstrated to enhance the clinical effectiveness of CRC, and their discovery is a growing area of research, as evidenced by the publication of over 100,000 papers on PubMed. However, sifting through this vast amount of literature is time‐consuming and may lead to loss of accuracy. To provide researchers with a comprehensive platform to search for accurate and categoric information for CRC biomarkers, we published the Colorectal Cancer Biomarker Database (CBD) in 2018, which gathered the curated data for all the reported 870 biomarkers for CRC [2]. Biomarkers in CBD are classified based on their biological sources into DNA, RNA, protein, and others. As a supplement to CBD, the Epigenetic Biomarker Database for Colorectal Cancer was developed in 2020 to collate epigenetic biomarkers for CRC [3]. Recently, some relevant biomarker databases have been reported, such as the MarkerDB [4] and the Cancer Biomarkers database [5]. However, the biomarkers for CRC are significantly lower than our CBD. With biomarkers from additional sources such as metabolite, microbiome, and image being reported in recent years, there is a growing need for continued development and expansion of biomarker databases for CRC.
Although identifying objects that are not viable biomarkers for CRC, as highlighted by negative experimental results, is a crucial aspect of biomarker studies, this aspect has received inadequate attention. To help researchers avoid such pitfalls and enhance the efficacy of biomarker discovery, a database specifically dedicated to the collection and dissemination of nonbiomarker information would be of great benefit.
Protein is the primary driver of the major physiological processes in the human body, and it constitutes the primary component of CRC biomarkers. Protein–protein interaction (PPI) networks facilitate the function of proteins by enabling their interaction with each other. In our previous study, we found that the biomarker–biomarker interaction (BBI) network exhibited distinct network features. However, specific BBI networks for specific groups of CRC biomarkers have not been investigated.
In this study, we present the CBD2 database (http://www.eyeseeworld.com/cbd), including a substantial number of newly discovered biomarkers, as well as nonbiomarkers, and incorporate network visualization and topology analysis functions. By introducing these features, CBD2 represents a user‐friendly and multifunctional platform that can aid in the discovery and development of CRC biomarkers. The overall pipeline of CBD2 is illustrated in the diagram (Figure 1).
DATABASE DESCRIPTION
In this work, we describe an updated version of the comprehensive CBD platform for CRC biomarkers, first proposed in 2018. The updated version, named CBD2, includes more detailed information on 1569 newly validated biomarkers and 150 nonbiomarkers. An innovative feature of CBD2 is the newly developed “Explore” page that combines the functions of the STRING API and igraph package. This feature enables users to easily query the interaction network of the biomarkers of interest. Further, the hyperlinks of functional enrichment analysis results are provided. All of these results are freely available for download.
Data summary
Compared with CBD, CBD2 updates 1569 biomarkers, bringing the total number of biomarkers to 2439. CBD2 expands the biological categories of biomarkers to DNA, RNA, protein, metabolite, microbiome, and image, as well as the clinical categories of diagnosis, treatment, and prognosis. Furthermore, CBD2 includes 150 nonbiomarkers, which refer to objects that have been deemed unsuitable for serving as CRC biomarkers. Notably, all biomarkers are annotated based on the DrugBank database, we provide information on known drug targets and corresponding drug molecules. A comparison of the data contained in CBD2 and CBD is conducted (Table 1). All the data included in CBD2 could be downloaded via the “Download” page.
| CBD | CBD2 | |
|---|---|---|
| Year range | 1986–2017 | 2018–Dec 2022 |
| Number of articles | 1115 | 2391 (+1276) |
| Number of biomarkers | 870 | 2439 (+1569) |
| Number of nonbiomarkers | \ | 150 |
| STRING network | \ | 1271 |
| Drug–target data | \ | 520 known targets |
| 4883 drugs |
Function
CBD2 presents a user‐friendly and multifunctional framework (Figure 2). Users can search for biomarker information on the “Biomarkers” page via categorical search, keyword search, or advanced search. After submitting a search query, a detail page for the specific biomarker is provided, encompassing detailed biomedicine information such as biological categories, ontology‐based descriptions, and a link to the relevant page of the NCBI database. Patient information, including the region, race, gender, and age of patients in the source study, as well as cancer information such as the location and stage of CRC, and experimental information such as the method, statistical results, application, conclusion, author, journal, published year, and PMID are also available. The information pertaining to nonbiomarkers is not categorized in detail and can be accessed on the “Non‐Biomarkers” page.
CBD2 incorporates drug–target information provided by DrugBank (v5.1.10) [6], enabling users to determine whether their searched biomarker is a drug target. On the detailed information page, users can access the PPI network for a specific protein biomarker by clicking the relevant button. The network is obtained from the STRING database [7], allowing users to manipulate and access structure and biomedicine information for each node protein. Additionally, some biomarker details may include annotated supplementary content.
CBD2 includes PPI information for all CRC protein biomarkers via the functions of the STRING API [7]. Users have the capability to investigate BBI networks by adhering to the parameter‐setting guidelines delineated on the “Explore” page. Additionally, a comprehensive elucidation of the implications of these parameters is furnished (Table S1). CBD2 provides three ways to query the BBI network: (1) directly selecting a biomarker stored in CBD2; (2) uploading a Txt or CSV file with one protein per line; (3) directly typing in a multiline text box. Then, the operational and visual BBI network will appear on the webpage.
Meanwhile, CBD2 employs the igraph package [8] to calculate network topological features of the BBI network and specific nodes, such as Degree, Betweenness, and Closeness. Biological functional analyses such as pathway enrichment analysis, gene ontology (GO) annotations, tissue expression, disease–gene association, annotated keywords in UniProt, protein domains and features, reference publications in PubMed, human phenotype from Monarch, and local network cluster are provided.
Users are welcome to submit the newly reported biomarkers on the “Submission” page.
CASE STUDY 1: INTEGRATED NETWORK ANALYSIS OF BIOMARKERS IN CBD2
To showcase the clinical relevance of the identified CRC biomarkers for diagnosis, treatment, and prognosis, we presented a case study that demonstrates the utility of CBD2 for analyzing biomarkers in a practical setting. We constructed the BBI networks for the existing diagnostic, therapeutic, and prognostic protein biomarkers in CBD2 (Figure S1) and calculated network parameters in the “Explore” page, followed by GO functional enrichment analysis and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis (Figure S2).
We found that the number of biomarkers used for the prognosis of CRC is significantly higher than those used for diagnosis and treatment, which is consistent with medical practice: (1) Various factors, such as tumor size, location, degree of differentiation, metastasis, and treatment options, could impact the survival period and quality of life of cancer patients after treatment. Therefore, multiple biomarkers were needed to comprehensively assess the prognosis. (2) Specific and precise biomarkers were needed to guide the determination of cancer type and stage and the selection of appropriate treatment methods. Therefore, diagnosis and treatment may require only a few biomarkers. What's more, early diagnosis and effective treatment of cancer remained significant challenges, which was also a crucial factor contributing to the relatively small number of biomarkers available for these purposes.
According to the boxplot of topological parameters (Figure 3), we noticed that the Closeness parameter had no obvious intergroup difference, while for Betweenness and Degree, the difference mainly appears in the Prognosis group and the other two marker groups.
The degree in PPI networks refers to the number of connections that a given protein has with other proteins, indicating its level of connectivity. Betweenness was a measure of the number of shortest paths that pass through a given protein, indicating its importance as a mediator of information flow within the network. Closeness measures the average shortest path between a protein and all other proteins in the network. It reflected how easily information can be transmitted from one protein to another in the network.
It is noteworthy that the scale of the network might influence these metrics, especially Degree. Larger networks might have a higher average degree, but this also depends on the sparsity or density of the network. For Betweenness, more “bridging” nodes might exist in larger networks, but this is not always the case since it depends on the specific structure of the network.
Considering the above situation, the following conclusions were indicated: (1) the lack of intergroup difference in the Closeness parameter suggested that the nodes in the different marker groups were similarly connected and can transmit information efficiently in the network. This may indicate that the selected biomarkers for CRC diagnosis, treatment, and prognosis were all functionally related and contributed to the overall network connectivity; (2) the differences in the Betweenness and Degree parameters between the prognosis group and the other two marker groups indicated that the nodes in the prognosis group have a greater influence on the network structure than the nodes in the diagnosis and treatment groups. This may imply that the selected biomarkers for CRC prognosis are more important for the overall network structure and function.
We performed an enrichment analysis of the resulting proteins. The obvious difference between the cellular components enriched for biomarkers for the diagnosis, treatment, and prognosis of CRC was that they reflect different aspects of the disease. The cellular components enriched for biomarkers for the diagnosis of CRC, such as the collagen‐containing extracellular matrix and platelet alpha granule, were primarily involved in the regulation of cell proliferation, migration, and invasion, which are important processes in cancer development and progression. The cellular components enriched for biomarkers for treatment of CRC, such as focal adhesion and cell–substrate junction, were involved in the regulation of cell adhesion, migration, and signaling, which were important processes in drug response and resistance. The cellular components enriched for biomarkers for CRC prognosis, such as secretory granule lumen and collagen‐containing extracellular matrix, were involved in the regulation of cell survival, proliferation, and metastasis, which were important processes in cancer recurrence and survival.
Analogously, comparable outcomes could be inferred regarding the molecular functions and biological processes of these biomarkers. However, we placed greater emphasis on the pathway enrichment of these biomarkers rather than on functional enrichment data. From the perspective of their respective enriched pathways, we found that there were highly overlapping co‐enriched pathways among biomarkers of different aspects of CRC. For example, “Proteoglycans in cancer” pathway was enriched in biomarkers for the diagnosis, treatment, and prognosis of CRC, suggesting that this pathway may play a key role in all stages of CRC. Likewise, the “PI3K‐Akt signaling pathway” was enriched in biomarkers for the diagnosis, treatment, and prognosis of CRC, while the pathway “EGFR tyrosine kinase inhibitor resistance” was enriched in biomarkers for the treatment and prognosis of CRC. These overlaps in enriched pathways suggests that some pathways may have multifaceted roles in CRC, and targeting them may have broader implications for the diagnosis, treatment, and prognosis of CRC. The network construction and analysis results of the above three types of biomarkers could be obtained with one click on our “Explore” page.
CASE STUDY 2: COMPARISON OF THE SAME BIOMARKER IN DIFFERENT STUDIES
Several biomarkers have undergone extensive investigations across multiple research endeavors, all of which have been meticulously curated and incorporated into the comprehensive CBD2 database. The investigation of biomarkers across multiple studies presents an intriguing avenue for exploration. As such, a comparative analysis of the impact of a specific biomarker within distinct research investigations holds substantial scientific merit.
Take p53 into consideration. In the realm of cellular biology, the p53 protein holds paramount importance in ensuring genomic stability. Under normal circumstances, this tumor suppressor protein acts as a gatekeeper, halting the progression of defective cells and directing them toward apoptosis or cellular senescence. This inherent ability of p53 to maintain cellular equilibrium is undermined when mutations or functional anomalies intervene. Mutated or aberrantly activated p53 often results in compromised tumor‐suppressive functions, allowing damaged cells to proliferate unchecked, subsequently amplifying the risk of tumorigenesis.
We searched CBD2 for collected p53‐related information and found that almost all the research related to it focused on prognosis. A summary of the research contents from six studies is presented (Table 2) [9, 10, 11, 12, 13, 14]. Across these investigations, a consistent observation was evident: patients with p53‐positive expression consistently faced a higher recurrence rate in comparison to those with p53‐negative status. This trend invariably translated to a notably reduced survival rate for the latter group.
| p53 | Patients number | Recurrence rate | Median survival (months) | 2‐Year survival rate | 3‐Year survival rate | 5‐Year survival rate | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ID | PMID | p53 positive | p53 negative | p53 positive | p53 negative | p53 positive | p53 negative | p53 positive | p53 negative | p53 positive | p53 negative | p53 positive | p53 negative |
| 1 | 1451055 | 39 | 61 | 23.8 | 5.9 | \ | \ | \ | \ | 61.8 | 96.7 | \ | \ |
| 19 | 7931472 | 50 | 57 | 60 | 35 | \ | \ | \ | \ | \ | \ | 48 | 78.9 |
| 31 | 8347496 | 121 | 82 | Higher | Lower | \ | \ | \ | \ | \ | \ | 58.1 | 76.3 |
| 42 | 8874329 | 72% | 28% | \ | \ | 21 | 53.2 | 41.7 | 78.6 | \ | \ | \ | \ |
| 78 | 9797697 | 44 | 25 | \ | \ | 27 | 93 | \ | \ | 31.5 | 71.8 | 21 | 53.1 |
| 202 | 12818291 | 38 | 37 | \ | \ | \ | \ | \ | \ | 63.2 | 86.5 | ||
CASE STUDY 3: NCRNA–GENE INTERACTION NETWORK
The elucidation of noncoding RNA (ncRNA)–gene interaction networks holds paramount significance in contemporary biomedical research. These intricate networks provide invaluable insights into the regulatory mechanisms governing gene expression and cellular processes. By unraveling the complex interplay between ncRNAs and genes, we gain a deeper understanding of their functional roles in physiological and pathological contexts. This knowledge has far‐reaching implications, ranging from the identification of novel therapeutic targets to the development of innovative diagnostic and prognostic tools. The exploration of ncRNA–gene interaction networks thus represents a crucial endeavor in advancing our understanding of molecular biology and its implications for human health.
Three and seventy‐four ncRNA biomarkers have been collected in CBD2, of which 210 belong to microRNA (miRNA). We finally parsed 251 standard miRNA identifiers from them. By constraining the Organism parameter to “H. sapiens (human)” and refining the Tissue parameter to “Intestine”, these miRNAs, in conjunction with 796 protein biomarkers from CBD2, were input into miRNet [15] with the aim of constructing a network elucidating the interactions between ncRNA and genes.
In the ncRNA–gene interaction network (Figure 4). We found that hsa‐mir‐92a‐3p, hsa‐mir‐103a‐3p, hsa‐mir‐21‐5p, hsa‐mir‐7‐5p, hsa‐mir‐34a‐5p, hsa‐mir‐30a‐5p, hsa‐mir‐26a‐5p, hsa‐mir‐186‐5p, and hsa‐mir‐362‐3p were the hubs in the network, seven of them are included in CBD2. We additionally conducted enrichment analysis utilizing both KEGG and DisGeNET on the delineated network, the results of which exhibited a pronounced correlation with CRC, underscoring the potential significance of the identified ncRNA–gene interactions in the context of this malignancy.
The files generated during the network construction process and relevant details are provided in the supplementary tables (Tables S2 – S5).
DISCUSSION
In this study, we have updated the CRC biomarker database (CBD2), which has included 2439 reported biomarkers for CRC. We have also added the BBI network analysis function to this update. We anticipate that the updated version of CBD2 will serve as a flexible and valuable tool for advancing CRC biomarker research, particularly with the addition of powerful network construction and analysis capabilities.
Except with our CBD2 database, other biomarker databases have been reported, such as the Global Online Biomarker Database, which amasses a plethora of benchmark biomarkers (https://gobiomdb.com/). Another significant repository is the Early Detection Research Network established by the US National Cancer Institute (https://edrn.nci.nih.gov/). Databases with more specific pathophysiological focuses include the US Environmental Protection Agency Biomarker Database catering to children's healthcare (https://cfpub.epa.gov/ncea/risk/recordisplay.cfm?deid=85844) [16], the Tuberculosis Biomarker Database specifically for tuberculosis (https://www.finddx.org/publication/tuberculosis-biomarker-database-2/) [17], and the Infectious Disease Biomarker Database dedicated to infectious diseases (http://biomarker.cdc.go.kr) [18]. Furthermore, for oncology‐centric research, there is the Gastric Cancer (Biomarkers) Knowledgebase for gastric cancer (http://biomarkers.bii.a-star.edu.sg/background/gastricCancerBiomarkersKb.php) [19], and the Liver Cancer Biomarker Reference Into Function (LiverCancerMarkerRIF) tailored for liver cancer (http://btm.tmu.edu.tw/LiverCancerMarkerRIF/) [20]. An eye biomarker database released by us provided a standardized platform for ocular biomarkers, and a driving force for future ophthalmic precision medicine [21]. These platforms offer invaluable insights for both the research community and clinical practitioners. Comparing with these databases, the CBD2 holds significant advantages:
- 1. Comprehensive focus on CRC: While many databases diversify their biomarker collection across multiple diseases, the CBD2 specifically concentrates on CRC, offering a depth of information unparalleled by more generalized repositories.
- 2. Advanced analytical tools: CBD2 is not just a data repository; it offers advanced analytical tools that enable users to conduct preliminary analyses. For example, we added network analysis capabilities to the database for the first time, providing users with new perspectives on the interaction level of biomarkers.
- 3. Rigorous quality control: Each entry in the CBD2 undergoes a rigorous review process, ensuring that the data is not only comprehensive but also of high quality, minimizing the risk of errors or inaccuracies.
- 4. Extensive metadata inclusion: CBD2 does not just provide biomarker data. It offers extensive metadata, giving researchers context about experimental conditions, patient demographics, and other relevant parameters.
- 5. Open access: Ensuring equitable access to knowledge, CBD2 operates on an open‐access model. Not only is its wealth of information freely available to researchers, clinicians, and the public at large without any barriers, but our website code and data tables are also openly available.
In future versions, we are planning to replace most of the manual reading work with methods based on natural language processing for biomedical text mining, retaining only a subset of experts for quality control. This will make the inclusion, exclusion, and information extraction of subsequent literature more efficient. We plan to update this database every 1–2 years.
In summary, the advancement of precision medicine in the field of CRC becomes more possible through the rich and expanded information provided by CBD2.
METHODS
Data collection and management
The literature search was performed on PubMed up to December 2022. We found 1276 new papers related to CRC biomarkers, and CBD2 currently contains information on CRC biomarkers from a total of 2391 papers. A collection of these papers is available on the CBD2's download page.
We selected papers that met the following criteria:
The study explicitly indicates that the object of study could be utilized as any biomarker for human CRC.
- 1.The study conducted experiments with control groups and demographic characteristics to validate their conclusions.
- 2.The experimental design and methods are described in detail in the paper.
- 3.Analyses conducted in the study ought to yield statistically significant outcomes. For instance, treatment or prognosis biomarkers must exhibit a p value for odds ratio, hazard ratio, or relative risk that is less than 0.05, underscoring the robustness of the findings.
- 4.The sample size in the study should be greater than 30.
In our review of selected articles, we meticulously extracted both biomarker‐specific details (such as the biomarker name, biological category, and description) and experimental information (inclusive of intricate details such as geographic region, racial background, sample size, gender, age, source, experimental method, statistical analysis, applications, conclusions), and article specifics (like first author, publishing journal, year of publication, and PubMed ID). The description of the collected information has been presented (Table 3).
| Items | Description |
|---|---|
| ID | Biomarker ID in the database |
| Name | Name of (non) biomarker |
| Category | Biological type of biomarker (e.g., protein, DNA) |
| NCBI protein | Protein information in the National Center for Biotechnology Information (NCBI) |
| Description | Description of biomarker |
| Region | The region where this biomarker research from |
| Race | The sample race of this biomarker research |
| Number | Sample number included in this biomarker research |
| Gender (male/female) | Gender distribution of sample number: Male/female |
| Age | Ages of samples: Mean age (minimum–maximum) |
| Location | Cancer location |
| Stage | Cancer stage |
| Source | Sample source |
| Experiment | Experiment method for research |
| Statistics | Statistics result for a biomarker in research |
| Application | Biomarker application |
| Clinical use | Whether the biomarker has been used in clinical practice |
| Conclusion | Research conclusion for this biomarker |
| Reference | First author, published Journal, and year of research |
| PMID | PubMed ID of research |
| STRING name | Name of the protein in the STRING database (If available) |
| STRING PPI | Show the protein–protein interaction (PPI) network of this protein with Other proteins with top 10 confidence scores (If STRING name is available) |
| Know target | Whether the current biomarker is a documented target in DrugBank |
| Drugs | Drugs on the target that have been recorded in DrugBank (if any) |
| Addition | Note by us |
To further ensure the reliability of our data, we assessed the quality of each selected paper. Utilizing the Critical Appraisal Skills Program (CASP, https://casp-uk.net/casp-tools-checklists/) checklists, we determined the confidence score of the papers. These checklists pose 11 questions designed to gauge the quality of a study's design, methodology, and results. For the majority of these questions, evaluators would respond with “Yes,” “No,” or “Can't tell” reflecting the paper's quality. A paper with answers comprising nine or more “Yes” would be regarded as of high quality. Those with answers between six and eight would be deemed of medium quality, while those with fewer than six “Yes” responses would be categorized as low quality. Studies that failed to meet more than five CASP criteria were excluded from our database.
Data cleaning
Standardization of geographic region names was achieved using the API provided by the GeoNames geographic database (https://www.geonames.org/). Further, for protein biomarkers, we accessed the corresponding STRING IDs and symbols from the STRING database (https://string-db.org/). Regarding the potential of a biomarker to serve as a drug target, we extracted pertinent data from DrugBank (RRID:SCR_002700) (https://go.drugbank.com/) for mapping purposes. In cases where the biomarker is identified as a known drug target, we also furnished comprehensive drug information pertaining to the biomarker from DrugBank.
Data analysis
We conducted a thorough extraction of protein and gene biomarkers specific to CRC, subsequently mapping these onto the human protein interaction network to engineer a BBI network. During the development of this network, certain topological characteristics were employed to depict the interconnectivity within the network. The realization of this functional component was achieved via the utilization of the STRING API and the Python package, igraph.
GO functional enrichment analysis and KEGG pathway enrichment analysis were conducted by the R package clusterProfiler [22].
Tools and software
CBD2 operates within a WNMP (Windows Server, Nginx, MySQL, PHP) environment hosted on a cloud server. The web interface is developed using a combination of HTML, PHP, and JavaScript technologies. The network analysis interface, on the other hand, is facilitated through the application of gradio (https://www.gradio.app/).
CONFLICT OF INTEREST STATEMENT
The authors declare no conflict of interest.
Supporting information
ACKNOWLEDGMENTS
This work was supported by the National Natural Science Foundation of China (Grant numbers: 32200545 and 32271292), and the GDPH Supporting Fund for Talent Program (Grant numbers: KJ012020633 and KJ012019530) from Guangdong Provincial People's Hospital. This work was also supported by the Guangdong Provincial Key Laboratory of Artificial Intelligence in Medical Image Analysis and Application (Grant number: 2022B1212010011). The sponsor or funding organization had no role in the design or conduct of this research.
Untitled section
Zhang, Xueli , Li Min, Ye Siting, Shen Ke, Yuan Haining, Bakhtyar Shoaib, Peng Qiliang, et al. 2024. “CBD2: A Functional Biomarker Database for Colorectal Cancer.” iMeta 3, e155. 10.1002/imt2.155
Untitled section
Footnote Group
Contributor Information
Guang Hu, Email: huguang@suda.edu.cn.
Hong Zhang, Email: hong.zhang@oru.se.
Xiao‐Feng Sun, Email: xiao-feng.sun@liu.se.
DATA AVAILABILITY STATEMENT
The data sets generated and analyzed during the study are available for download at: http://www.eyeseeworld.com/cbd/Download.html. The code used to build our database in this study is open source and available on GitHub at: https://github.com/WhyLIM/CBD. Supplementary materials (figures, tables, scripts, graphical abstract, slides, videos, Chinese translated version and update materials) may be found in the online DOI or iMeta Science http://www.imeta.science/.
REFERENCES
Untitled section
References
- 1. Granados‐Romero, Juan José , Valderrama‐Treviño Alan Isaac, Contreras‐Flores Ericka Hazzel, Barrera‐Mera Baltazar, Herrera Enríquez Miguel, Uriarte‐Ruíz Karen, Ceballos‐Villalba Jesús Carlos, et al. 2017. “Colorectal Cancer: A Review.” International Journal of Research in Medical Sciences 5: 4667–4676. 10.18203/2320-6012.IJRMS20174914
- 2. Zhang, Xueli , Sun Xiao‐Feng, Cao Yang, Ye Benchen, Peng Qiliang, Liu Xingyun, Shen Bairong, and Zhang Hong. 2018. “CBD: A Biomarker Database for Colorectal Cancer.” Database 2018: bay046. 10.1093/database/bay046
- 3. Liu, Xingyun , Zhang Xueli, Chen Jing, Ye Benchen, Ren Shumin, Lin Yuxin, Sun Xiao‐Feng, Zhang Hong, and Shen Bairong. 2020. “CRC‐EBD: Epigenetic Biomarker Database for Colorectal Cancer.” Frontiers in Genetics 11: 907. 10.3389/fgene.2020.00907
- 4. Wishart, David S. , Bartok Brendan, Oler Eponine, Liang Kevin Y. H., Budinski Zachary, Berjanskii Mark, Guo AnChi, Cao Xuan, and Wilson Michael. 2021. “MarkerDB: An Online Database of Molecular Biomarkers.” Nucleic Acids Research 49: D1259–D1267. 10.1093/nar/gkaa1067
- 5. Tamborero, David , Rubio‐Perez Carlota, Deu‐Pons Jordi, Schroeder Michael P., Vivancos Ana, Rovira Ana, Tusquets Ignasi, et al. 2018. “Cancer Genome Interpreter Annotates the Biological and Clinical Relevance of Tumor Alterations.” Genome Medicine 10: 25. 10.1186/s13073-018-0531-8
- 6. Wishart, David S. , Feunang Yannick D., Guo An C., Lo Elvis J., Marcu Ana, Grant Jason R., Sajed Tanvir, et al. 2018. “DrugBank 5.0: A Major Update to the DrugBank Database for 2018.” Nucleic Acids Research 46: D1074–D1082. 10.1093/nar/gkx1037
- 7. Szklarczyk, Damian , Gable Annika L., Lyon David, Junge Alexander, Wydervcc Stefan, Huerta‐Cepas Jaime, Simonovic Milan, et al. 2019. “STRING v11: Protein–Protein Association Networks with Increased Coverage, Supporting Functional Discovery in Genome‐Wide Experimental Datasets.” Nucleic Acids Research 47: D607–D613. 10.1093/nar/gky1131
- 8. Csárdi, Gábor , and Nepusz T.. 2006. “The igraph Software Package for Complex Network Research.” InterJournal Complex Systems: 1695. 10.5281/zenodo.3630268
- 9. Belluco, C. , Guillem J. G., Kemeny N., Huang Y., Klimstra D., Berger M. F., and Cohen A. M.. 1996. “p53 Nuclear Protein Overexpression in Colorectal Cancer: A Dominant Predictor of Survival in Patients with Advanced Hepatic Metastases.” Journal of Clinical Oncology 14: 2696–2701. 10.1200/JCO.1996.14.10.2696
- 10. Lashner, Bret A. , Bauer William M., Rybicki Lisa A., and Goldblum John R.. 2003. “Abnormal p53 Immunohistochemistry is Associated with an Increased Colorectal Cancer‐Related Mortality in Patients With Ulcerative Colitis.” The American Journal of Gastroenterology 98: 1423–1427. 10.1111/j.1572-0241.2003.07573.x
- 11. Nitti, D. , Belluco C., Montesco M. C., Bertorelle R., Da Pian P. P., Fassina A., Ninfo V., Chieco‐Bianchi L., and Lise M.. 1998. “Nuclear p53 Protein Expression in Resected Hepatic Metastases from Colorectal Cancer: An Independent Prognostic Factor of Survival.” European Journal of Cancer 34: 851–855. 10.1016/s0959-8049(97)10165-4
- 12. Yamaguchi, Akio , Kurosaka Yoshiyuki, Fushida Sachio, Kanno Masuhiro, Yonemura Yutaka, Miwa Kouichi, and Miyazaki Itsuo. 1992. “Expression of p53 Protein in Colorectal Cancer and its Relationship to Short‐Term Prognosis.” Cancer 70: 2778–2784. 10.1002/1097-0142(19921215)70:12<2778::AID-CNCR2820701209>3.0.CO;2-L
- 13. Yamaguchi, A. , Nakagawara G., Kurosaka Y., Nishimura G., Yonemura Y., and Miyazaki I.. 1993. “p53 Immunoreaction in Endoscopic Biopsy Specimens of Colorectal Cancer, and its Prognostic Significance.” British Journal of Cancer 68: 399–402. 10.1038/bjc.1993.348
- 14. Zeng, Z. S. , Sarkis A. S., Zhang Z. F., Klimstra D. S., Charytonowicz E., Guillem J. G., Cordon‐Cardo C., and Cohen A. M.. 1994. “p53 Nuclear Overexpression: An Independent Predictor of Survival in Lymph Node‐Positive Colorectal Cancer Patients.” Journal of Clinical Oncology 12: 2043–2050. 10.1200/JCO.1994.12.10.2043
- 15. Chang, Le , Zhou Guangyan, Soufan Othman, and Xia Jianguo. 2020. “miRNet 2.0: Network‐Based Visual Analytics for miRNA Functional Analysis and Systems Biology.” Nucleic Acids Research 48: W244–W251. 10.1093/nar/gkaa467
- 16. Lobdell, Danelle T. , and Mendola Pauline. 2005. “Development of a Biomarkers Database for the National Children's Study.” Toxicology and Applied Pharmacology 206: 269–273. 10.1016/j.taap.2004.07.016
- 17. Yerlikaya, Seda , Broger Tobias, MacLean Emily, Pai Madhukar, and Denkinger Claudia M.. 2017. “A Tuberculosis Biomarker Database: The Key to Novel TB Diagnostics.” International Journal of Infectious Diseases 56: 253–257. 10.1016/j.ijid.2017.01.025
- 18. Yang, In Seok , Ryu Chunsun, Cho Ki Joon, Kim Jin Kwang, Ong Swee Hoe, Mitchell Wayne P., Kim Bong Su, Oh Hee‐Bok, and Kim Kyung Hyun. 2007. “IDBD: Infectious Disease Biomarker Database.” Nucleic Acids Research 36: D455–D460. 10.1093/nar/gkm925
- 19. Lee, Bernett T. K. , Song Chun Meng, Yeo Boon Huat, Chung Cheuk Wang, Chan Ying Leong, Lim Teng Ting, Chua Yen Bing, et al. 2007. “Gastric Cancer (Biomarkers) Knowledgebase (GCBKB): A Curated and Fully Integrated Knowledgebase of Putative Biomarkers Related to Gastric Cancer.” Biomarker Insights 1: 135–141. 10.1177/117727190600100005
- 20. Dai, Hong‐Jie , Wu Johnny Chi‐Yang, Lin Wei‐San, Reyes Aaron James F., Dela Rosa Mira Anne C., Syed‐Abdul Shabbir, Tsai Richard Tzong‐Han, and Hsu Wen‐Lian. 2014. “LiverCancerMarkerRIF: A Liver Cancer Biomarker Interactive Curation System Combining Text Mining and Expert Annotations.” Database 2014: bau085. 10.1093/database/bau085
- 21. Zhang, Xueli , Kong Lingcong, Liu Shunming, Zhang Xiayin, Shang Xianwen, Zhu Zhuoting, Huang Yu, et al. 2023. “EBD: an Eye Biomarker Database.” Bioinformatics 39: btad194. 10.1093/bioinformatics/btad194
- 22. Wu, Tianzhi , Hu Erqiang, Xu Shuangbin, Chen Meijun, Guo Pingfan, Dai Zehan, Feng Tingze, et al. 2021. “clusterprofiler 4.0: A Universal Enrichment Tool for Interpreting Omics Data.” Innovation 2: 100141. 10.1016/j.xinn.2021.100141
Associated Data
Supplementary Materials
Data Availability Statement
The data sets generated and analyzed during the study are available for download at: http://www.eyeseeworld.com/cbd/Download.html. The code used to build our database in this study is open source and available on GitHub at: https://github.com/WhyLIM/CBD. Supplementary materials (figures, tables, scripts, graphical abstract, slides, videos, Chinese translated version and update materials) may be found in the online DOI or iMeta Science http://www.imeta.science/.